STAT+: We’re reading about an FDA quality lab lease, Marty Makary’s confirmation hearing, and more
The Trump Administration reversed course on plans to terminate the lease of a major Food and Drug Administration quality lab
Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans recommended to me by a colleague*, looking forward to a dinner tonight with my father and feeling quite warm and grateful for the people in my life. Anyway, here’s the news, which I’m sure will be equally wholesome and not at all depressing. …
The Trump Administration reversed course on plans to terminate the lease of a major Food and Drug Administration quality lab, Endpoints News reports. The St. Louis facility was one of about 30 FDA facilities whose leases Elon Musk’s Department of Government Efficiency marked for cancellation. Its work is critical for ensuring medicines reach quality control standards and investigating potential drug contamination.
Marty Makary, nominee for FDA commissioner, is likely to face questions about firings at the agency during his confirmation hearing today, STAT predicts. Like NIH nominee Jay Bhattacharya yesterday, the Johns Hopkins surgeon, author and medical iconoclast will likely be pressed by senators about the effects Musk’s Department of Government Efficiency has already had on the agency. Other potential topics include: rare disease therapies, revamping the FDA’s food center, handling an influx of AI-enabled devices, and evaluating vaccines.
